Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
68Ga-PSMA-11 PET/CT Imaging for the Detection of Prostate Cancer
August 21, 2025 | 3:30 PM ET
As with any diagnostic modality, there can be challenges associated with understanding the clinical utility of advanced imaging. Telix Physician Education & Engagement is pleased to offer this educational program focused on 68Ga-PSMA-11 (also known as gallium 68 gozetotide, trade name Illuccix/Gozellix®) for PET/CT imaging of Prostate Cancer.
Esteban Regalado, RN
Esteban Regalado, RN, is the Director of Physician Education and Engagement at Telix Pharmaceuticals.
Umesh Oza, MD
Umesh Oza, MD, is the Chief of Nuclear Medicine and Chair of Radiology at Baylor University Medical Center-Dallas and faculty at Texas A&M Medical School. He attended medical school at the University of Texas Health Science Center at Houston and Tufts University, School of Medicine. He completed a fellowship in Nuclear Medicine at Harvard Medical School.
This is a non-CME, company-led program developed and sponsored by Telix Physician Education & Engagement, intended for healthcare professionals only. The content of this company-directed program is not sponsored or endorsed by the American Urological Association (AUA).